BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 27121473)

  • 1. Candidate driver genes involved in genome maintenance and DNA repair in Sézary syndrome.
    Woollard WJ; Pullabhatla V; Lorenc A; Patel VM; Butler RM; Bayega A; Begum N; Bakr F; Dedhia K; Fisher J; Aguilar-Duran S; Flanagan C; Ghasemi AA; Hoffmann RM; Castillo-Mosquera N; Nuttall EA; Paul A; Roberts CA; Solomonidis EG; Tarrant R; Yoxall A; Beyers CZ; Ferreira S; Tosi I; Simpson MA; de Rinaldis E; Mitchell TJ; Whittaker SJ
    Blood; 2016 Jun; 127(26):3387-97. PubMed ID: 27121473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome.
    da Silva Almeida AC; Abate F; Khiabanian H; Martinez-Escala E; Guitart J; Tensen CP; Vermeer MH; Rabadan R; Ferrando A; Palomero T
    Nat Genet; 2015 Dec; 47(12):1465-70. PubMed ID: 26551667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome.
    Kiel MJ; Sahasrabuddhe AA; Rolland DCM; Velusamy T; Chung F; Schaller M; Bailey NG; Betz BL; Miranda RN; Porcu P; Byrd JC; Medeiros LJ; Kunkel SL; Bahler DW; Lim MS; Elenitoba-Johnson KSJ
    Nat Commun; 2015 Sep; 6():8470. PubMed ID: 26415585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in Sézary syndrome.
    Caprini E; Bresin A; Cristofoletti C; Helmer Citterich M; Tocco V; Scala E; Monopoli A; Benucci R; Narducci MG; Russo G
    Cell Death Dis; 2018 Dec; 9(12):1178. PubMed ID: 30518749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of key regions and genes important in the pathogenesis of sezary syndrome by combining genomic and expression microarrays.
    Caprini E; Cristofoletti C; Arcelli D; Fadda P; Citterich MH; Sampogna F; Magrelli A; Censi F; Torreri P; Frontani M; Scala E; Picchio MC; Temperani P; Monopoli A; Lombardo GA; Taruscio D; Narducci MG; Russo G
    Cancer Res; 2009 Nov; 69(21):8438-46. PubMed ID: 19843862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic rearrangements result in altered gene expression and novel fusion transcripts in Sézary syndrome.
    Iżykowska K; Przybylski GK; Gand C; Braun FC; Grabarczyk P; Kuss AW; Olek-Hrab K; Bastidas Torres AN; Vermeer MH; Zoutman WH; Tensen CP; Schmidt CA
    Oncotarget; 2017 Jun; 8(24):39627-39639. PubMed ID: 28489605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypomethylation of the promoter region drives ectopic expression of TMEM244 in Sézary cells.
    Iżykowska K; Rassek K; Żurawek M; Nowicka K; Paczkowska J; Ziółkowska-Suchanek I; Podralska M; Dzikiewicz-Krawczyk A; Joks M; Olek-Hrab K; Giefing M; Przybylski GK
    J Cell Mol Med; 2020 Sep; 24(18):10970-10977. PubMed ID: 32794659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetics Abnormalities with Clinical Impact in Primary Cutaneous Lymphomas.
    Gallardo F; Pujol RM
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sézary syndrome: old enigmas, new targets.
    Nicolay JP; Felcht M; Schledzewski K; Goerdt S; Géraud C
    J Dtsch Dermatol Ges; 2016 Mar; 14(3):256-64. PubMed ID: 26972187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCL2 and JUNB abnormalities in primary cutaneous lymphomas.
    Mao X; Orchard G; Lillington DM; Child FJ; Vonderheid EC; Nowell PC; Bagot M; Bensussan A; Russell-Jones R; Young BD; Whittaker SJ
    Br J Dermatol; 2004 Sep; 151(3):546-56. PubMed ID: 15377339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analysis of PTEN status in Sezary syndrome.
    Cristofoletti C; Picchio MC; Lazzeri C; Tocco V; Pagani E; Bresin A; Mancini B; Passarelli F; Facchiano A; Scala E; Lombardo GA; Cantonetti M; Caprini E; Russo G; Narducci MG
    Blood; 2013 Nov; 122(20):3511-20. PubMed ID: 24062018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3.
    Booken N; Gratchev A; Utikal J; Weiss C; Yu X; Qadoumi M; Schmuth M; Sepp N; Nashan D; Rass K; Tüting T; Assaf C; Dippel E; Stadler R; Klemke CD; Goerdt S
    Leukemia; 2008 Feb; 22(2):393-9. PubMed ID: 18033314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expression of cell adhesion molecule 1 and its splicing variants in Sézary cells and cell lines from cutaneous T-cell lymphoma.
    Yamaguchi M; Morizane S; Hamada T; Miyake T; Sugaya M; Iwata H; Fujii K; Haramoto-Shiratsuki R; Nakagawa Y; Miura M; Ohshima K; Morishita K; Takahashi T; Imada M; Okada K; Uehara J; Sowa-Osako J; Iwatsuki K
    J Dermatol; 2019 Nov; 46(11):967-977. PubMed ID: 31515833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Insights Into the Complex Mutational Landscape of Sézary Syndrome.
    Mirza AS; Horna P; Teer JK; Song J; Akabari R; Hussaini M; Sokol L
    Front Oncol; 2020; 10():514. PubMed ID: 32373524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NOTCH1 signaling as a therapeutic target in Sézary syndrome.
    van der Fits L; Qin Y; Out-Luiting JJ; Vermeer KG; Whittaker S; van Es JH; Tensen CP; Vermeer MH
    J Invest Dermatol; 2012 Dec; 132(12):2810-7. PubMed ID: 22718117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes.
    Wang L; Ni X; Covington KR; Yang BY; Shiu J; Zhang X; Xi L; Meng Q; Langridge T; Drummond J; Donehower LA; Doddapaneni H; Muzny DM; Gibbs RA; Wheeler DA; Duvic M
    Nat Genet; 2015 Dec; 47(12):1426-34. PubMed ID: 26551670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel and highly recurrent chromosomal alterations in Sézary syndrome.
    Vermeer MH; van Doorn R; Dijkman R; Mao X; Whittaker S; van Voorst Vader PC; Gerritsen MJ; Geerts ML; Gellrich S; Söderberg O; Leuchowius KJ; Landegren U; Out-Luiting JJ; Knijnenburg J; Ijszenga M; Szuhai K; Willemze R; Tensen CP
    Cancer Res; 2008 Apr; 68(8):2689-98. PubMed ID: 18413736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells.
    Zhang C; Li B; Gaikwad AS; Haridas V; Xu Z; Gutterman JU; Duvic M
    J Invest Dermatol; 2008 Nov; 128(11):2728-2735. PubMed ID: 18496567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic and prognostic importance of T-cell receptor gene analysis in patients with Sézary syndrome.
    Fraser-Andrews EA; Russell-Jones R; Woolford AJ; Wolstencroft RA; Dean AJ; Whittaker SJ
    Cancer; 2001 Oct; 92(7):1745-52. PubMed ID: 11745245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sézary Syndrome: Translating Genetic Diversity into Personalized Medicine.
    Chevret E; Merlio JP
    J Invest Dermatol; 2016 Jul; 136(7):1319-1324. PubMed ID: 27342034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.